TIRZ / IGF-1 LR3Interpret the evidence
What a digestion experiment can tell us about an IGF-1 LR3 variant
2 numbered sourcesSource years 1996, 2026
A peptide is a short chain of amino acids connected by peptide bonds. Enzymes can cut those bonds, and a change in sequence can affect where they cut. Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified, extended growth-factor protein. An older study investigated which changes to LR3 made the resulting molecules more resistant to a digestive enzyme. [1, 2]
The researchers tested purified pepsin from pigs in the laboratory. They identified places where the enzyme cut the original IGF-1 LR3 molecule, then made related variants with individual amino-acid substitutions. One of the modified variants resisted breakdown more strongly under the tested conditions. Some other changes did not provide the same effect. These comparisons were possible because the team tested the parent molecule and the variants in the same experimental system. [1]
A change in susceptibility to one digestive enzyme is a chemical observation. It does not establish absorption or activity in a person. The FDA label for tirzepatide describes a separate physiological effect on how quickly the stomach empties. The two pieces of evidence concern different processes. One is an enzyme experiment on LR3 and related molecules. The other is information about an approved tirzepatide product and its effect on stomach function. [1, 2]
Neither source tested the exact pair. The pepsin experiment shows that even a one-residue change can affect a particular laboratory measurement. It therefore helps explain why researchers keep the parent growth factor, its engineered variants and any proposed formulation with another ingredient distinct when describing their results. [1, 2]
Sources
Original works cited in this article. Links open the external record in a new tab.
